P2RY12 and myocardial infarction: In the unadjusted analysis, the group receiving potent P2Y12 inhibitors exhibited a significantly lower risk of mortality within the first year after myocardial infarction, with an HR of 0.58 (95% CI: 0.54–0.63), compared to those on clopidogrel.